Translational Cancer Research · 2021 · 17 citations · 31 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular PharmacologyCancer ImmunotherapyColorectal CancerDrug-target Interaction NetworksNetwork PharmacologyOncology PharmacologySystems Pharmacology In CancerAnticancer ActivityCompound-disease Network ConstructionCompound-protein-disease Network AnalysisGene Ontology EnrichmentNetwork Medicine In CancerPharmacological Network AnalysisTraditional Chinese MedicineTraditional Medicine Network Pharmacology
BACKGROUND: Colorectal cancer (CRC) is the third most prevalent cancer globally. In the treatment of CRC, surgical resection is commonly adopted, and neoadjuvant chemotherapy or immunotherapy is mainly administered for patients with advanced disease. However, despite the developments in the field of cancer treatment, the mortality rate of CRC has remained high. Therefore, novel treatments for CRC need to be explored. Astragalus membranaceus, commonly known in China as Huangqi (HQ), a traditional Chinese medicine, has been reported to be a potential antitumorigenic agent. This study aimed to investigate the mechanisms of action of HQ. METHODS: Active ingredients and putative targets of HQ were obtained through a comprehensive search of the Traditional Chinese Medicine Systems Pharmacology database. CRC-related targets were retrieved from the GeneCards database and then overlapping targets were acquired. After visualization of the compound-disease network and protein-protein interaction (PPI) network, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the overlapping genes were performed. Additionally, HCT116 cells were treated with the active components of HQ at a 20-µM concentration. Cell Counting Kit-8 was used to detect cell activity, and real-time quantitative polymerase chain reaction was carried out to detect the expression of genes downstream of the interleukin (IL)-17 signaling pathway. RESULTS: experiments showed that HQ promoted the apoptosis of CRC cells by inhibiting the expression of the CCL2, CXCL8, CXCL10, and PTGS2 genes. CONCLUSIONS: This study systematically revealed the multitarget mechanism of HQ in CRC through a network pharmacology approach. We verified that HQ promotes CRC cell death via the IL-17 signaling pathway. This finding provides indications for further mechanistic studies and the development of HQ as a potential treatment for CRC patients.
31
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan, Luigi Nezi, Alexandre Reuben et al. · Science · 2017 · 4.7K citations · Full text
Life Sciences, Immunology, Oncology +17
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
Vyara Matson, Jessica Fessler, Riyue Bao et al. · Science · 2018 · 3K citations
Life Sciences, Immunology, Oncology +17
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Kristin M. Nieman, Hilary A. Kenny, Carla Penicka et al. · Nature Medicine · 2011 · 2.3K citations
Medicine, Cancer Biology, Oncology +14